GSE30009: Multidrug resistance-linked gene signature predicts overall...

Description Format Details Value

Description

This study assesses the ability of multidrug resistance (MDR)-associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy.We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes.Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels.This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer.

Format

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
experimentData(eset):
Experiment data
  Experimenter name: Gillet JP, Calcagno AM, Varma S, Davidson B et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 2012 Jun 1;18(11):3197-206.
  Laboratory: Gillet, Gottesman 2012
  Contact information:
  Title: Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
  URL:
  PMIDs: 22492981

  Abstract: A 244 word abstract is available. Use 'abstract' method.
  Information is available on: preprocessing
  notes:
   platform_title:
      TaqMan qRT-PCR Homo sapiens Low-Density Array 380
   platform_shorttitle:
      TaqMan qRT-PCR
   platform_summary:
      NA
   platform_manufacturer:
      TaqMan
   platform_distribution:
      custom
   platform_accession:
      GPL13728
   version:
      2015-09-22 19:46:26

featureData(eset):
An object of class 'AnnotatedDataFrame'
  featureNames: 5 6 ... 380 (363 total)
  varLabels: probeset gene EntrezGene.ID best_probe
  varMetadata: labelDescription

Details

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
assayData: 363 features, 103 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)

      n  events  median 0.95LCL 0.95UCL
 103.00   57.00    3.42    2.92    5.34

---------------------------
Available sample meta-data:
---------------------------

alt_sample_name:
 Norwegian patient 1 Norwegian patient 10 Norwegian patient 11
                   1                    1                    1
Norwegian patient 12 Norwegian patient 13 Norwegian patient 14
                   1                    1                    1
Norwegian patient 15 Norwegian patient 16 Norwegian patient 17
                   1                    1                    1
Norwegian patient 18 Norwegian patient 19  Norwegian patient 2
                   1                    1                    1
Norwegian patient 20 Norwegian patient 21 Norwegian patient 22
                   1                    1                    1
Norwegian patient 23  Norwegian patient 3  Norwegian patient 4
                   1                    1                    1
 Norwegian patient 5  Norwegian patient 6  Norwegian patient 7
                   1                    1                    1
 Norwegian patient 8  Norwegian patient 9         US Patient 1
                   1                    1                    1
       US Patient 10        US Patient 11        US Patient 12
                   1                    1                    1
       US Patient 13        US Patient 14        US Patient 15
                   1                    1                    1
       US Patient 16        US Patient 17        US Patient 18
                   1                    1                    1
       US Patient 19         US Patient 2        US Patient 20
                   1                    1                    1
       US Patient 21        US Patient 22        US Patient 23
                   1                    1                    1
       US Patient 24        US Patient 25        US Patient 26
                   1                    1                    1
       US Patient 27        US Patient 28        US Patient 29
                   1                    1                    1
        US Patient 3        US Patient 30        US Patient 31
                   1                    1                    1
       US Patient 32        US Patient 33        US Patient 34
                   1                    1                    1
       US Patient 35        US Patient 36        US Patient 37
                   1                    1                    1
       US Patient 38        US Patient 39         US Patient 4
                   1                    1                    1
       US Patient 40        US Patient 41        US Patient 42
                   1                    1                    1
       US Patient 43        US Patient 44        US Patient 45
                   1                    1                    1
       US Patient 46        US Patient 47        US Patient 48
                   1                    1                    1
       US Patient 49         US Patient 5        US Patient 50
                   1                    1                    1
       US Patient 51        US Patient 52        US Patient 53
                   1                    1                    1
       US Patient 54        US Patient 55        US Patient 56
                   1                    1                    1
       US Patient 57        US Patient 58        US Patient 59
                   1                    1                    1
        US Patient 6        US Patient 60        US Patient 61
                   1                    1                    1
       US Patient 62        US Patient 63        US Patient 64
                   1                    1                    1
       US Patient 65        US Patient 66        US Patient 67
                   1                    1                    1
       US Patient 68        US Patient 69         US Patient 7
                   1                    1                    1
       US Patient 70        US Patient 71        US Patient 72
                   1                    1                    1
       US Patient 73        US Patient 74        US Patient 75
                   1                    1                    1
       US Patient 76        US Patient 77        US Patient 78
                   1                    1                    1
             (Other)
                   4

sample_type:
tumor
  103

histological_type:
clearcell       ser
        1       102

summarygrade:
high  low NA's
  92    9    2

summarystage:
late
 103

tumorstage:
 3  4
82 21

substage:
   b    c NA's
   2   60   41

grade:
   1    2    3 NA's
   4    5   92    2

age_at_initial_pathologic_diagnosis:
   Min. 1st Qu.  Median    Mean 3rd Qu.    Max.
  30.00   56.00   61.00   62.45   71.50   87.00

days_to_death:
   Min. 1st Qu.  Median    Mean 3rd Qu.    Max.
     24     598    1053    1156    1568    4748

vital_status:
deceased   living
      57       46

debulking:
   optimal suboptimal
        81         22

uncurated_author_metadata:
                                                                                                            title: Norwegian patient 10///geo_accession: GSM742654///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1903///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6///characteristics_ch1.11: overall survival (os; months): 26///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT10///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                   title: Norwegian patient 11///geo_accession: GSM742655///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 30///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 933///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT11///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                     title: Norwegian patient 12///geo_accession: GSM742656///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 42///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 99///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 52///characteristics_ch1.11: overall survival (os; months): 56///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT12///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                       title: Norwegian patient 13///geo_accession: GSM742657///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 241///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT13///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                       title: Norwegian patient 14///geo_accession: GSM742658///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 2966///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 52///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT14///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                       title: Norwegian patient 15///geo_accession: GSM742659///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 637///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 36///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT15///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                   title: Norwegian patient 16///geo_accession: GSM742660///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 50///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 492///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT16///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                               title: Norwegian patient 17///geo_accession: GSM742661///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 79///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 230///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT17///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: Norwegian patient 18///geo_accession: GSM742662///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1354///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT18///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                       title: Norwegian patient 19///geo_accession: GSM742663///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1145///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jum-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT19///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: Norwegian patient 1///geo_accession: GSM742645///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1100///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 5///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT1///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: Norwegian patient 20///geo_accession: GSM742664///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 305///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 29///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT20///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: Norwegian patient 21///geo_accession: GSM742665///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 937///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT21///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                  title: Norwegian patient 22///geo_accession: GSM742666///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2359///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 31///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT22///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                title: Norwegian patient 23///geo_accession: GSM742667///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1400///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-1999///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT23///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                               title: Norwegian patient 2///geo_accession: GSM742646///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 700///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT2///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                    title: Norwegian patient 3///geo_accession: GSM742647///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 75///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1965///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 77///characteristics_ch1.11: overall survival (os; months): 83///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT3///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: Norwegian patient 4///geo_accession: GSM742648///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 761///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 42///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: 2002 jan///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT4///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                           title: Norwegian patient 5///geo_accession: GSM742649///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 24290///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 4///characteristics_ch1.11: overall survival (os; months): 34///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT5///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                              title: Norwegian patient 6///geo_accession: GSM742650///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 1331///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT6///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                               title: Norwegian patient 7///geo_accession: GSM742651///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 375///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 7///characteristics_ch1.11: overall survival (os; months): 27///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT7///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                           title: Norwegian patient 8///geo_accession: GSM742652///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 40790///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo+taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 10///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Jul-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT8///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: Norwegian patient 9///geo_accession: GSM742653///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1395///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 65///characteristics_ch1.11: overall survival (os; months): 72///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: NPT9///description.1: Norwegian Radium Hospital///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                 title: US Patient 10///geo_accession: GSM742574///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 69///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 306///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 15///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT10///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                           title: US Patient 11///geo_accession: GSM742575///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 536///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/cc2103///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT11///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: US Patient 12///geo_accession: GSM742576///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 293///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: modifed triple doublets///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.8///characteristics_ch1.11: overall survival (os; months): 68.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT12///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                         title: US Patient 13///geo_accession: GSM742577///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 26.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT13///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: US Patient 14///geo_accession: GSM742578///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 793///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 64.8///characteristics_ch1.11: overall survival (os; months): 64.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT14///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                      title: US Patient 15///geo_accession: GSM742579///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2792///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.2///characteristics_ch1.11: overall survival (os; months): 23.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT15///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                      title: US Patient 16///geo_accession: GSM742580///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2983///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.6///characteristics_ch1.11: overall survival (os; months): 34.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT16///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                     title: US Patient 17///geo_accession: GSM742581///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 48///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3723///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18.2///characteristics_ch1.11: overall survival (os; months): 33///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT17///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: US Patient 18///geo_accession: GSM742582///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 63///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Unknown///characteristics_ch1.5: preop. ca125: 3078///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 21.2///characteristics_ch1.11: overall survival (os; months): 52.4///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT18///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                       title: US Patient 19///geo_accession: GSM742583///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8942///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 2.7///characteristics_ch1.11: overall survival (os; months): 6.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT19///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                   title: US Patient 1///geo_accession: GSM742565///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 87///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1584///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17.5///characteristics_ch1.11: overall survival (os; months): 50///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT1///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                           title: US Patient 20///geo_accession: GSM742584///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 9603///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 37.6///characteristics_ch1.11: overall survival (os; months): 37.6///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT20///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                              title: US Patient 21///geo_accession: GSM742585///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 210///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxotere/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 2.6///characteristics_ch1.11: overall survival (os; months): 36.9///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Mar-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT21///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                               title: US Patient 22///geo_accession: GSM742586///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP/IV platinum/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13.6///characteristics_ch1.11: overall survival (os; months): 31///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT22///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                            title: US Patient 23///geo_accession: GSM742587///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 20000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.9///characteristics_ch1.11: overall survival (os; months): 46.9///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT23///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                        title: US Patient 24///geo_accession: GSM742588///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 696///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin/Avastin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 48.3///characteristics_ch1.11: overall survival (os; months): 48.3///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Apr-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT24///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                           title: US Patient 25///geo_accession: GSM742589///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 84///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 103///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 33.1///characteristics_ch1.11: overall survival (os; months): 33.1///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT25///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: US Patient 26///geo_accession: GSM742590///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 789///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxane///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12///characteristics_ch1.11: overall survival (os; months): 47.3///characteristics_ch1.12: status: alive with disease (AWD) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT26///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                       title: US Patient 27///geo_accession: GSM742591///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 62///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 802///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 9.5///characteristics_ch1.11: overall survival (os; months): 31.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT27///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                                  title: US Patient 28///geo_accession: GSM742592///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 64///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 988///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 44.2///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT28///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                      title: US Patient 29///geo_accession: GSM742593///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1139///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: tcA///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 5.5///characteristics_ch1.11: overall survival (os; months): 15.1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT29///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                   title: US Patient 2///geo_accession: GSM742566///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 43///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 564///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/gem/toxo/doxil///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 75///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT2///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                           title: US Patient 30///geo_accession: GSM742594///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 450///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: t/c, carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.2///characteristics_ch1.11: overall survival (os; months): 40.1///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT30///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                title: US Patient 31///geo_accession: GSM742595///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2301///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 12.2///characteristics_ch1.11: overall survival (os; months): 31.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Sep-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT31///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                    title: US Patient 32///geo_accession: GSM742596///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1684///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 8.7///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT32///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                                 title: US Patient 33///geo_accession: GSM742597///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2106///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 0.8///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT33///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                      title: US Patient 34///geo_accession: GSM742598///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 2///characteristics_ch1.5: preop. ca125: 990///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10.1///characteristics_ch1.11: overall survival (os; months): 18.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT34///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                 title: US Patient 35///geo_accession: GSM742599///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 281///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 27.8///characteristics_ch1.12: status: no evidence of disease (NED) ?///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT35///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                   title: US Patient 36///geo_accession: GSM742600///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 206///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 20.2///characteristics_ch1.11: overall survival (os; months): 51///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT36///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                           title: US Patient 37///geo_accession: GSM742601///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 44///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3738///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 10.4///characteristics_ch1.11: overall survival (os; months): 24.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT37///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                         title: US Patient 38///geo_accession: GSM742602///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2389///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: Unknown///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 9.3///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT38///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: US Patient 39///geo_accession: GSM742603///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 65///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 104///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 32.7///characteristics_ch1.11: overall survival (os; months): 32.7///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jul-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT39///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                      title: US Patient 3///geo_accession: GSM742567///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 404///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 0///characteristics_ch1.11: overall survival (os; months): 12///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT3///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                               title: US Patient 40///geo_accession: GSM742604///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, transitional///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1591///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 54///characteristics_ch1.11: overall survival (os; months): 54///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT40///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                     title: US Patient 41///geo_accession: GSM742605///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1072///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 1.4///characteristics_ch1.11: overall survival (os; months): 9.4///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: resistant///characteristics_ch1.14: diagnostic date: Feb-06///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT41///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                     title: US Patient 42///geo_accession: GSM742606///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 146///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/Gemcitabine, carboplatin/taxol, adriamycin/topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19.8///characteristics_ch1.11: overall survival (os; months): 41.2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT42///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                     title: US Patient 43///geo_accession: GSM742607///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 26///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 25.7///characteristics_ch1.11: overall survival (os; months): 53///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Nov-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT43///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                        title: US Patient 44///geo_accession: GSM742608///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 534///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.1///characteristics_ch1.11: overall survival (os; months): 36.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT44///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                          title: US Patient 45///geo_accession: GSM742609///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 334///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: IP taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 8.6///characteristics_ch1.11: overall survival (os; months): 10.6///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT45///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                                   title: US Patient 46///geo_accession: GSM742610///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 600///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 6.7///characteristics_ch1.11: overall survival (os; months): 18.3///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT46///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                             title: US Patient 47///geo_accession: GSM742611///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 55///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: Carcinoma arising in borderline///characteristics_ch1.5: preop. ca125: 619///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16.8///characteristics_ch1.11: overall survival (os; months): 16.8///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Aug-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT47///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                               title: US Patient 48///geo_accession: GSM742612///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 229///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: t/c///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 14///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-07///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT48///description.1: MGH (Boston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                          title: US Patient 49///geo_accession: GSM742613///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3252///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (15X), tamoxifen, taxol (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT49///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                         title: US Patient 4///geo_accession: GSM742568///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 12033///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 1///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT4///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                title: US Patient 50///geo_accession: GSM742614///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 862.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X) then surgery and then taxol (6X), carboplatin (6x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT50///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
title: US Patient 51///geo_accession: GSM742615///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 76///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3000///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ cisplatin (6X), carboplatin (6X),carbo (5x), topotecan (23x), gemcitabine (12x), tamoxifen, doxil (18x), xeloda (15x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 5///characteristics_ch1.11: overall survival (os; months): 90///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT51///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                        title: US Patient 52///geo_accession: GSM742616///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 1///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Apr-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT52///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                           title: US Patient 53///geo_accession: GSM742617///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 53///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carbo (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 17///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT53///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                      title: US Patient 54///geo_accession: GSM742618///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11.7///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin (9x), taxol (12x), tamoxifen, XRt, xeloda (4x), doxil (9x), carboplatin (7x), arimidex///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 18///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT54///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                title: US Patient 55///geo_accession: GSM742619///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 338.3///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6x), carboplatin (4x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 19///characteristics_ch1.11: overall survival (os; months): 38///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT55///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                          title: US Patient 56///geo_accession: GSM742620///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 51///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 5140///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: cisplatin/taxol (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 151///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Mar-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT56///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                 title: US Patient 57///geo_accession: GSM742621///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3398///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/cisplatin (7x), taxol/carboplatin (3x), carbo (6x), whole brain XRt, intra-thecal topotecan and iv topotecan (1x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 22///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Oct-97///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT57///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                        title: US Patient 58///geo_accession: GSM742622///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 77///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 548///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (3x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-96///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT58///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                 title: US Patient 59///geo_accession: GSM742623///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 66///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 298///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin (6X), subopt tRS, interferon (2x), carboplatin (12x), tamoxifen, doxorubicin (9x), taxol (3x), topotecan///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 68///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jul-98///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT59///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                     title: US Patient 5///geo_accession: GSM742569///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 57///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1130///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol/cpt11/tam/topo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 15///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT5///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                  title: US Patient 60///geo_accession: GSM742624///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 61///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: Elevated///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carboplatin/cytoxan (8X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 156///characteristics_ch1.11: overall survival (os; months): 156///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jun-95///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT60///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                 title: US Patient 61///geo_accession: GSM742625///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 82///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous, endometrioid///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 981///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 24///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT61///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                             title: US Patient 62///geo_accession: GSM742626///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 68///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2373.4///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 35///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT62///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                title: US Patient 63///geo_accession: GSM742627///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 56///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 382///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X),carboplatin(3X), doxil(12X), taxol/ avastin(5X), topotecan(3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT63///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                        title: US Patient 64///geo_accession: GSM742628///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 144///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 66///characteristics_ch1.11: overall survival (os; months): 66///characteristics_ch1.12: status: no evidence of disease (NED)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jun-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT64///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                 title: US Patient 65///geo_accession: GSM742629///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 67///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 11713///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), caboplatin (11X), taxotere (6X), doxil (24X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 16///characteristics_ch1.11: overall survival (os; months): 63///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT65///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                           title: US Patient 66///geo_accession: GSM742630///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 72///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3705.6///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: carboplatin/topotecan(4X), carbo/taxol(4X), doxil(4X), topotecan(2X), taxotere (3X), Xelado (3X), taxol (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 13///characteristics_ch1.11: overall survival (os; months): 41///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT66///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                             title: US Patient 67///geo_accession: GSM742631///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 71///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2353///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: none///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 2///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT67///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                        title: US Patient 68///geo_accession: GSM742632///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 74///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 715///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (2x), letrozole///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 28///characteristics_ch1.11: overall survival (os; months): 64///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT68///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                 title: US Patient 69///geo_accession: GSM742633///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 89.1///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), carboplatin (6x), tamoxifen///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 36///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Jan-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT69///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                  title: US Patient 6///geo_accession: GSM742570///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 40///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3B///characteristics_ch1.4: tumor grade: 1///characteristics_ch1.5: preop. ca125: 523///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: CR///characteristics_ch1.8: chemotherapy: carbo/taxol///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 46///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: sensitive///characteristics_ch1.14: diagnostic date: accrued from Apr-01 to Aug-05///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT6///description.1: Cleveland Clinic///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
      title: US Patient 70///geo_accession: GSM742634///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 49///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 3444.5///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (5X)/carboplatin (6X), taxol (9x), carboplatin (4x), doxil (4x), topotecan (3x), navelbine (2x), gemcitabine (2x)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 32///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Feb-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT70///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                  title: US Patient 71///geo_accession: GSM742635///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 78///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 311///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PR///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), tamoxifen, femara///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 17///characteristics_ch1.11: overall survival (os; months): 47///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT71///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                  title: US Patient 72///geo_accession: GSM742636///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 8.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X), taxol (6X), carboplatin (2X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 28///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Nov-01///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT72///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                             title: US Patient 73///geo_accession: GSM742637///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 59///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 156///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (8X), carboplatin (3X)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): unknown///characteristics_ch1.11: overall survival (os; months): 37///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Oct-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT73///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                   title: US Patient 74///geo_accession: GSM742638///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 52///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 165///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin & doxil (6X), taxol/ carboplatin (6X), carboplatin///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 23///characteristics_ch1.11: overall survival (os; months): 57///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Aug-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT74///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                      title: US Patient 75///geo_accession: GSM742639///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 73///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 176///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: patient decided to have chemo elsewhere (standard treatment recommendation is carbo/taxol 6X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 60///characteristics_ch1.11: overall survival (os; months): 60///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: May-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT75///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                            title: US Patient 76///geo_accession: GSM742640///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 45///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 4///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 2215///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol/ carboplatin (6X), topotecan (4X), carboplatin (4X)///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 21///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-03///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT76///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                      title: US Patient 77///geo_accession: GSM742641///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 58///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3C///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1693///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: Unknown///characteristics_ch1.8: chemotherapy: taxol (9X), then taxol/carboplatin (one dose only due to severe neuropathy)///characteristics_ch1.9: surgical debulking or residual disease (cm): >1///characteristics_ch1.10: progression-free survival (pfs; months): 49///characteristics_ch1.11: overall survival (os; months): 65///characteristics_ch1.12: status: alive with disease (AWD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Dec-02///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT77///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                            title: US Patient 78///geo_accession: GSM742642///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 10.8///characteristics_ch1.6: preop. ca125 defined as high or low: LOW///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT78///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                           title: US Patient 79///geo_accession: GSM742643///status: Public on Apr 19 2012///submission_date: Jun 15 2011///last_update_date: Apr 19 2012///type: RNA///channel_count: 1///source_name_ch1: Primary tumor///organism_ch1: Homo sapiens///characteristics_ch1: age: 60///characteristics_ch1.1: tissue: ovarian carcinoma///characteristics_ch1.2: histology: serous///characteristics_ch1.3: figo stage: 3///characteristics_ch1.4: tumor grade: 3///characteristics_ch1.5: preop. ca125: 1920///characteristics_ch1.6: preop. ca125 defined as high or low: HIGH///characteristics_ch1.7: response: PD///characteristics_ch1.8: chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo///characteristics_ch1.9: surgical debulking or residual disease (cm): <1///characteristics_ch1.10: progression-free survival (pfs; months): 10///characteristics_ch1.11: overall survival (os; months): 14///characteristics_ch1.12: status: dead of disease (DOD)///characteristics_ch1.13: platinum sensitivity: unknown///characteristics_ch1.14: diagnostic date: Mar-04///treatment_protocol_ch1: Untreated tumors.///growth_protocol_ch1: The tumor was fresh-frozen at -80C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).///label_ch1: FAM///label_protocol_ch1: cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturers instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.///taxid_ch1: 9606///hyb_protocol: n/a///scan_protocol: ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).///description: PT79///description.1: MDA (Houston)///data_processing: SDS files were processed in RQ manager software and raw data were then exported in XLS file.///platform_id: GPL13728///contact_name: jean-pierre,,gillet///contact_email: gilletjp@mail.nih.gov///contact_phone: 301-435-6307///contact_laboratory: LCB///contact_department: NCI///contact_institute: NIH///contact_address: 37 Convent Drive///contact_city: Bethesda///contact_state: MD///contact_zip.postal_code: 20892///contact_country: USA///supplementary_file: NONE///data_row_count: 380
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (Other)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      4

Value

An expression set


MetaGxOvarian documentation built on May 2, 2018, 4:20 a.m.